Experts on the Forefront of Inflammasome Research Will Serve on ZyVersa Therapeutics' Inaugural Immunology Scientific Advisory Board

Tuesday, May 21, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

ZyVersa's lead anti-inflammatory candidate is a novel monoclonal antibody targeting the ASC component of inflammasomes, inhibiting both the intracellular and extracellular inflammatory response cascade for treatment of people with debilitating inflammatory diseases



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store